Introduction {#s1}
============

Globally, liver cancer is a highly malignant tumor with high prevalence and poor outcomes, which results in \~850,000 new cases per year ([@B1]). As the major subtype of liver cancer, hepatocellular carcinoma (HCC) accounts for 85--90% of all liver cancer cases ([@B1]) and has become the second leading cause of cancer-associated deaths ([@B2]). It has been reported that the 5-year survival rate is 30.5% in patients with local HCC while \<5% in patients with distant metastasis ([@B3]). At present, partial hepatectomy and liver transplantation are still the main treatments for early-stage patients, but a significant proportion of patients are not eligible for these treatments. Furthermore, the postoperative recurrence or distant metastasis is prevalent in patients after surgery ([@B4]). Although the systemic therapy with sorafenib is regarded as a first-line chemotherapeutic therapy in patients with advanced HCC, the high resistance rate has significantly limited the benefit of sorafenib therapy ([@B5]). Therefore, there is an urgent need to find a novel and effective therapy to improve the clinical outcomes of HCC patients.

The initiation, development, metastasis, and recurrence of HCC are closely related to the immune system ([@B6]). It has been reported that dysregulation of the immune system including alteration in the number or function of immune cells ([@B7]) and the release of chemokine and cytokine ([@B8]) result in the progression of HCC. Accordingly, immunotherapy has attracted increasing attention in HCC. As an important breakthrough in the field of immunotherapy, immune checkpoint inhibitors target three main molecules: cytotoxic T-lymphocyte-associated molecule-4 (*CTLA-4*), programmed cell death receptor-1 (*PD-1*), and programmed cell death ligand-1 (*PD-L1*) ([@B9]). It has been reported that camrelizumab showed antitumor activity and manageable toxicities in advanced HCC patients by blocking the interaction between *PD-1* and its ligands ([@B10]). Another clinical trial ([@B11]) also indicated that tremelimumab (*CTLA-4* blockade) showed antitumor and antiviral activities in advanced HCC patients. Nevertheless, only a minority of patients can respond to these immunotherapies, and fewer still achieve a lasting response ([@B12]). Consequently, it is one of the critical challenges to explore the molecular mechanism of immunotherapeutic responsiveness in HCC.

Tumor mutational burden (TMB) was defined as the total number of errors in somatic gene coding, base substitution, gene insertion, or deletion detected in every million base. Accumulation of somatic mutation contributes to the occurrence of tumor and the expression of neoantigens ([@B13]). Meanwhile, it has been reported that TMB can be used to predict the efficacy of immune checkpoint blockade and become a useful biomarker in some cancers for identification of patients who will benefit from immunotherapy ([@B14]). However, the potential association between gene mutation and immunotherapy in HCC is still unclear.

In this research, we firstly identified that *CTNNB1* was one of the frequently mutated genes in HCC and highly associated with survival and TMB. Next, we explored the relationship between *CTNNB1* mutation and immune cell infiltration and found that natural killer (NK) cells significantly infiltrated the *CTNNB1* mutation group. Therefore, we further investigated the correlation between *CTNNB1* mutation and immune inhibitors. We finally found that *CD96* was negatively associated with CTNNB1 mutation and speculated that *CTNNB1* may modulate NK cells by affecting *CD96*. Our research proposed a new underlying association between *CTNNB1* mutation and immunotherapy in HCC, which may help in improving the efficacy of immunotherapy in HCC patients.

Materials and Methods {#s2}
=====================

Data Collection
---------------

The somatic gene mutation data, gene expression data, and clinical messages were retrieved from International Cancer Genome Consortium (ICGC) database (<https://dcc.icgc.org/>) and The Cancer Genome Atlas (TCGA) database (<https://portal.gdc.cancer.gov/>). Three independent cohorts (LIRI-JP, LICA-FR, and LINC-JP) in ICGC database were employed in our research. All the three cohorts were used for mutational gene selection, and the LIRI-JP cohort was employed for further analyses (owing to gene expression data and more known clinical parameters). In addition, the TCGA-LIHC cohort was used for further validation.

Selection of Key Mutational Genes
---------------------------------

Based on the "GenVisR" package under the R studio software, the details of mutation from the three cohorts were visualized in waterfall plot. After that, we employed the intersection of the three cohorts for further analyses and used the Venn plot to visualize. To investigate the time-dependent prognostic value of included genes, the survival analysis was performed using the "survival" package. Moreover, we explored the association between included genes and TMB. To calculate the TMB of each case, the total number of mutations counted was divided by the exome size (38 Mb was utilized as the exome size). The mutational genes were eligible for further analyses if they were significantly different in both the survival analysis and TMB correlation analysis. A *P*-value \< 0.05 was considered a significant difference in this section. Besides, the mutational analysis and TMB correlation analysis were performed again based on the TCGA-LIHC cohort for validation.

Immune Cell Infiltration and Immune Inhibitors
----------------------------------------------

To explore the underlying mechanism between mutational gene and immune cells, we estimated the abundance of immune cell infiltration with different mutational status in the cases of the LIRI-JP cohort on the basis of the CIBERSORT algorithm. CIBERSORT is a deconvolution algorithm that evaluates the proportions of 22 tumor-infiltrating lymphocyte subsets. The number of permutations was set to 1,000, and the sample in the cohort was eligible for further validation if a *P*-value \< 0.05. Meanwhile, the results of immune cell infiltration were verified in TIMER website (<http://timer.cistrome.org/>) on the basis of the TCGA-LIHC cohort. Besides, we investigated the correlation between 22 types of immune cells and survival. In addition, we evaluated the correlation between gene mutation and the expression of immunoinhibitory genes from TISIDB website (<http://cis.hku.hk/TISIDB/index.php>) ([@B15]). Both *P* \< 0.05 and mean difference of median-value \> 0.6 were considered significant association in TISIDB website.

Gene Set Enrichment Analysis
----------------------------

Gene set enrichment analysis (GSEA) is a computational method that identifies whether a prior defined set of genes shows statistically significant differences between two biological states ([@B16]). In this research, we performed the GSEA to identify statistically different pathways from Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases between the mutation group and wild-type group. The normalized enrichment score was used to evaluate the pathways, and the top 5 significant pathways in two groups were visualized using the "ggplot" package.

Results {#s3}
=======

Identification of Key Mutational Genes
--------------------------------------

First of all, we summarized the flowchart, as shown in [Figure 1](#F1){ref-type="fig"}. The clinical details of the ICGC cohorts are shown in [Table 1](#T1){ref-type="table"}. As illustrated in [Figure 2](#F2){ref-type="fig"}, the details of the top 20 most frequently mutated genes are demonstrated in waterfall plots. Interestingly, we observed that some genes frequently mutated in all the three cohorts. So we executed a comparative analysis of the 20 most frequently mutated genes among the three cohorts. The Venn plot in [Figure 2D](#F2){ref-type="fig"} shows that nine genes (*ALB, APOB, ARID1A, ARID2, CTNNB1, MUC16, PCLO, TP53*, and *TTN*) were included in the intersection of the three cohorts. After that, we performed a survival analysis to evaluate nine genes. The results of the survival analysis in [Figure 3](#F3){ref-type="fig"} indicated that a significant difference was found between the mutation group and wild-type group in the three genes (*CTNNB1, PCLO*, and *TP53*). Furthermore, we evaluated the correlation between the three genes and TMB, and the results indicated that only *CTNNB1* mutation was statistically significant with TMB in the three cohorts. Therefore, we focused on *CTNNB1* mutation in subsequent analyses. In addition, the validation of the TCGA-LIHC cohort demonstrated that *CTNNB1* was one of the frequently mutated genes ([Figure 4A](#F4){ref-type="fig"}) and positively related to TMB in HCC ([Figure 4B](#F4){ref-type="fig"}).

![The flowchart of this study.](fonc-10-00853-g0001){#F1}

###### 

Baseline patient characteristic in three cohorts.

  **Clinical characteristics**          **Number**     **Percent**   
  ------------------------------------- -------------- ------------- ------
  **LICA-FR (*****n*** **=** **369)**                                
  Survival status                       Survival       92            25
                                        Death          115           31
                                        Not reported   162           44
  Age                                   ≤65 years      205           56
                                        \>65 years     164           44
  Gender                                Female         76            21
                                        Male           293           79
  T classification                      T1             54            14.6
                                        T2             65            17.6
                                        T3             40            10.8
                                        T4             1             0.3
                                        Not reported   209           56.7
  N classification                      N0             160           43
                                        N1             0             0
                                        Not reported   209           57
  M classification                      M0             159           43
                                        M1             1             0.3
                                        Not reported   209           56.7
  **LINC-JP (*****n*** **=** **394)**                                
  Survival status                       Survival       269           68
                                        Death          79            20
                                        Not reported   46            12
  Age                                   ≤65 years      175           45
                                        \>65 years     206           52
                                        Not reported   13            3
  Gender                                Female         95            24
                                        Male           299           76
  Stage                                 I              16            4.1
                                        II             69            17.5
                                        III            67            17
                                        IV             43            10.9
                                        Not reported   199           50.5
  **LIRI-JP (*****n*** **=** **260)**                                
  Survival status                       Survival       214           82.4
                                        Death          46            17.6
  Age                                   ≤65 years      98            37.7
                                        \>65 years     162           62.3
  Stage                                 I              40            15.4
                                        II             117           45
                                        III            80            30.8
                                        IV             23            8.8

![Waterfall plot with the details of gene mutation from three cohorts. **(A)** The waterfall plot of LICA-FR. **(B)** The waterfall plot of LINC-JP. **(C)** The waterfall plot of LIRI-JP. **(D)** The Venn plot of three cohorts.](fonc-10-00853-g0002){#F2}

![Survival analysis and tumor mutational burden (TMB) correlation analysis.](fonc-10-00853-g0003){#F3}

![Validation based on TCGA-LIHC cohort. **(A)** The waterfall plot of TCGA-LIHC. **(B)** Tumor mutational burden (TMB) correlation analysis.](fonc-10-00853-g0004){#F4}

Immune Cell Infiltration and Immune Inhibitors
----------------------------------------------

As shown in [Figure 5](#F5){ref-type="fig"}, the relative percent of 22 immune cell infiltration was visualized based on the LIRI-JP cohort. Between the mutation group and wild-type group, significant differences were found (*P* \< 0.05) in five types of immune cells (CD8 T cells, regulatory T cells, gamma delta T cells, activated NK cells, and neutrophils) on the basis of the LIRI-JP cohort ([Figure 5](#F5){ref-type="fig"}). In the TCGA-LIHC cohort, significant differences were found ([Figure 5](#F5){ref-type="fig"}) in six types of immune cells (mast cell activated, monocyte, neutrophil, NK cell activated, T cell CD4^+^ memory resting, and T cell CD4^+^ naive). Both NK cell activated and neutrophil were significantly infiltrated the mutation group of two cohorts. In addition, the results of [Figure 6](#F6){ref-type="fig"} show that CTNNB1 mutation was negatively associated with *CD96, HAVCR2, LGALS9*, and *TGFB1*. And the expression difference of median between the two groups was −0.965 (*CD96*), −0.679 (*HAVCR2*), −0.733 (*LGALS9*), and −0.951 (*TGFB1*). Moreover, [Figure 7A](#F7){ref-type="fig"} demonstrates that a significant difference was found between the live group and deceased group in dendritic cell activated and NK cell activated. Consequently, we focused on NK cells and further explored the correlation between NK cells and clinical parameters. The results from [Figure 7B](#F7){ref-type="fig"} show that a significantly positive correlation was found between stage and NK cell infiltration in HCC. The verification from [Figures 7C--F](#F7){ref-type="fig"} also indicates that the expression and methylation of CTNNB1 were significantly associated with CD96 expression and NK cell abundance.

![Immune cell infiltration from LIRI cohort and LIHC cohort.](fonc-10-00853-g0005){#F5}

![The heatmap of 24 types of immune inhibitors and significant results from correlation analysis.](fonc-10-00853-g0006){#F6}

![Correlation analysis. **(A)** The correlation between 22 types of immune cells and survival. **(B)** The correlation between NK cells and clinical parameters. **(C,D)** The correlation between CTNNB1 expression and CD96, and NK cells, respectively. **(E,F)** The correlation between CTNNB1 methylation and CD96, and NK cells, respectively. Notes: "\*" in the plots means *P* \< 0.05, "\*\*" means *P* \< 0.01.](fonc-10-00853-g0007){#F7}

Underlying Pathways Associated With CTNNB1 Mutation
---------------------------------------------------

To investigate underlying pathways of GO and KEGG, we used GSEA to find significantly enriched terms by comparing the mutation and wild-type groups. We selected the 10 most relevant pathways according to the normalized enrichment score (five pathways in the mutation group and five in the wild-type group). As illustrated in [Figure 8](#F8){ref-type="fig"}, 10 relevant pathways (oxidoreductase activity acting on the aldehyde or oxo group of donors, sulfur amino acid metabolic process, C4 dicarboxylate transport, organic acid catabolic process, and xenobiotic metabolic process in GO; tyrosine metabolism, fatty acid metabolism, butanoate metabolism, metabolism of xenobiotics by cytochrome P450, and primary bile acid biosynthesis in KEGG) are enriched in the mutation group, whereas other 10 pathways (negative regulation of axon extension, positive regulation of astrocyte differentiation, plasma membrane phospholipid scrambling, plasma membrane organization, and cellular component maintenance in GO; renal cell carcinoma, regulation of actin cytoskeleton, bladder cancer, notch signaling pathway, and focal adhesion in KEGG) enriched in the wild-type group.

![The results of gene set enrichment analysis (GSEA) based on Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases.](fonc-10-00853-g0008){#F8}

Discussion {#s4}
==========

With the increasing exploration of the immune system, immunotherapy was considered to have a crucial role in treatment of cancer. It has been verified that TMB was closely related to immune checkpoint inhibitors. However, the mechanism between gene mutation and immunotherapy in HCC was still unclear. Consequently, in our research, we firstly analyzed the details of gene mutation from the three cohorts. Then we performed a comparative analysis to find the intersection of the three cohorts, and we found that only three mutational genes were significantly associated with overall survival. Among the three genes, only *CTNNB1* was significantly associated with TMB in all three cohorts. Therefore, *CTNNB1* was selected for further investigation. *CTNNB1* (catenin beta-1) is a key regulatory molecule of canonical Wnt signaling pathway. An activating mutation in exon 3 of *CTNNB1* results in accumulation of β-catenin in the nucleus and activates the transcription of downstream target gene such as lymphoid enhancer-binding factor 1 (*LEF1*) ([@B17]), and *LEF1* is a transcription factor that has been implicated in the pathogenesis of multiple tumors ([@B18]). It has been reported that *CTNNB1* mutation was highly associated with many kinds of human tumors, such as biliary tract cancer ([@B19]), lung adenocarcinoma ([@B20]), and endometrioid ovarian carcinoma ([@B21]). In our research, *CTNNB1* mutation was significantly associated with a better prognosis and a higher TMB. A higher TMB leads to the exposure of more neoantigens, which may cause a T cell-dependent immune response ([@B22]). Meanwhile, previous studies ([@B23], [@B24]) indicated that *CTNNB1* significantly mutated in immune subtypes of HCC. As a result, *CTNNB1* mutation may have an effect on immunotherapy. To further explore the mechanism between *CTNNB1* mutation and immunotherapy, we compared the difference of immune cell infiltration between the mutation group and wild-type group. Interestingly, we found that NK cells significantly positively infiltrated the mutation group. Meanwhile, the results indicated that more NK cells significantly infiltrated the survival group. Accordingly, we focused on NK cells in subsequent analyses.

NK cell is an important part of the innate immune system, which can secrete cytokines and cytolytic activity against target cells. It has been verified that NK cells can efficiently eradicate heterogeneous tumor cells after a long-term treatment ([@B25]). Concerning HCC, the lack of NK cell number and the defects of NK cell function facilitated the escape of tumor cells from immune surveillance ([@B26]). In patients with advanced-stage HCC, NK cells were significantly decreased in number with impaired tumor necrosis factor alpha (TNF-α) and interferon-gamma (IFN-γ) production ([@B27]). Our results also showed the positive correlation between NK cell infiltration and stage. However, no significant correlation was found between NK cell infiltration and other clinical parameters like age and gender, which may attribute to the small sample size. Based on the implication of CTNNB1 mutation and NK cells in HCC, we speculated that *CTNNB1* mutation may enhance the effect of immunotherapy by NK cells.

Furthermore, we investigated the correlation between *CTNNB1* mutation and immunoinhibitory genes. In our research, we found that *CTNNB1* mutation was negatively associated with four immunoinhibitory genes. Among them, *CD96* is the novel immune checkpoint receptor in NK cells ([@B28]). Accumulating data support the targeting of *CD96* for improving antitumor immune response ([@B29]). Galectin-9 (*LGALS9*) is the most relevant ligand that interacts with Tim-3 (*HAVCR2*) ([@B30]). Binding of Tim-3 (*HAVCR2*) to galectin-9 (*LGALS9*) leads to Th1 cell death by apoptosis ([@B30]). Meanwhile, Tim-3 (*HAVCR2*) is an inducible human NK cell receptor that enhances IFN-γ production in response to galectin-9 (*LGALS9*) ([@B31]). In terms of *TGFB1*, it has been reported that *TGFB1* suppresses the function of NK cells by inducing miRNA23a ([@B32]). Four types of immune inhibitors showed the close association with NK cells, which verified the relationship between *CTNNB1* mutation and NK cells. On the one hand, our result indicated that *CD96* was most negatively correlated with CTNNB1 mutation. On the other hand, not only the mutation but also the expression and methylation of *CTNNB1* significantly related to *CD96* and NK cells. Consequently, we speculated that there is an underlying interactive association among CTNNB1, CD96, and NK cells. Considering the signaling pathways associated with *CTNNB1* mutation, we employed GSEA to find the significantly enriched pathways in the mutation group. Although we did not find any pathways related to immune response, five pathways involved metabolism were observed. Immune activation is now understood to be fundamentally linked to intrinsic and/or extrinsic metabolic process. It has been reported that carbohydrate and amino acid metabolism are hallmarks for the innate immune cell activation and function ([@B33]). Meanwhile, immune cells exhibit various responses against different types of microbes, which seems to be associated with changes in energy metabolism ([@B34]). But it is uncertain whether *CTNNB1* mutation affects the immunotherapy through metabolic pathways.

To our knowledge, it is the first research that focused on the gene mutation and immunotherapy in HCC. Our research revealed the implication of *CTNNB1* mutation in the immunotherapy of HCC. Furthermore, because *CTNNB1* mutation positively associated with immune inhibitors, *CTNNB1* mutation may serve as the novel biomarker in identifying the patients who will benefit from immune checkpoint blockade treatment. Nevertheless, some limitations in our research have to be pointed out. First, NK cells can be divided into subsets based on the expression of CD56 and CD16. It is necessary to investigate the mechanism among different NK cell subsets, CTNNB1 and CD96 in HCC. Second, the results of GSEA were preliminary; the current evidences of pathways still need to be validated in clinical trials and functional experiments.

Conclusion {#s5}
==========

Our research firstly revealed the underlying association between *CTNNB1* mutation and immunotherapy, and we speculated that *CTNNB1* mutation may modulate NK cells by affecting CD96. However, more functional experiments should be performed for verification.
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